Literature DB >> 24451277

Diagnostic utility of targeted next-generation sequencing in problematic cases.

Jennifer K Sehn1, Ian S Hagemann, John D Pfeifer, Catherine E Cottrell, Christina M Lockwood.   

Abstract

Targeted next-generation sequencing (NGS) provides predictive and prognostic information in the routine care of patients with cancer. However, with increasing knowledge of the biological basis of cancer, NGS of the same gene sets can also provide diagnostic information in challenging cases, on the basis of identification of both known and novel variants, including single-nucleotide variants, insertions and deletions, copy number alterations, and translocations. Here, we present 3 clinical cases in which targeted NGS of hybrid-capture-enriched DNA from formalin-fixed, paraffin-embedded tumor samples provided unique and clinically important diagnostic and/or staging information in 3 different challenging clinical scenarios. In the first patient, NGS played a key role in both diagnosis and staging in a patient with multiple tumors of the same histologic type. The second case demonstrates the ability of NGS to clarify the tumor tissue type in a single mass involving multiple organs, and thereby guide appropriate chemotherapy. The third case illustrates that information regarding susceptibility to targeted therapeutics can also clarify the original histologic diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24451277     DOI: 10.1097/PAS.0000000000000161

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Authors:  Benjamin A Weinberg; Kyle Gowen; Thomas K Lee; Sai-Hong Ignatius Ou; Robert Bristow; Lauren Krill; M Isabel Almira-Suarez; Siraj M Ali; Vincent A Miller; Stephen V Liu; Samuel J Klempner
Journal:  Oncologist       Date:  2017-02-13

2.  MET Mutation Associated with Responsiveness to Crizotinib.

Authors:  Saiama N Waqar; Daniel Morgensztern; Jennifer Sehn
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

3.  Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.

Authors:  Nabil F Saba; Malania Wilson; Gregory Doho; Juliana DaSilva; R Benjamin Isett; Scott Newman; Zhuo Georgia Chen; Kelly Magliocca; Michael R Rossi
Journal:  Head Neck Pathol       Date:  2014-09-19

4.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors:  Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

Authors:  Hussam Al-Kateb; TuDung T Nguyen; Karen Steger-May; John D Pfeifer
Journal:  Mol Oncol       Date:  2015-05-29       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.